Showing results (51-60 of 63) with videos related to

Sort By:
Pageof 7
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1991
Primary and salvage chemotherapy in advanced Hodgkin's disease: the Milan Cancer Institute experienceG Bonadonna, A Santoro, A M Gianni, et al.
European Journal of Cancer & Clinical Oncology|July 1, 1987
The clinical significance of melatonin serum determination in oncological patients and its correlations with GH and PRL blood levelsP Lissoni, A Bastone, R Sala, et al.
British Journal of Haematology|November 25, 1998
Ifosfamide and vinorelbine: an active regimen for patients with relapsed or refractory Hodgkin's diseaseV Bonfante, S Viviani, A Santoro, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1992
Early stage Hodgkin's disease: ten-year results of a non-randomised study with radiotherapy alone or combined with MOPPV Bonfante, A Santoro, S Viviani, et al.
Leukemia Research|October 10, 2017
Early reduction of serum TARC levels may predict for success of ABVD as frontline treatment in patients with Hodgkin LymphomaA Guidetti, A Mazzocchi, R Miceli, et al.
The Cancer Journal From Scientific American|October 20, 1999
Long-term results of an intensive regimen: VEBEP plus involved-field radiotherapy in advanced Hodgkin's diseaseS Viviani, V Bonfante, A Santoro, et al.
Leukemia & Lymphoma|November 8, 2001
Anaplastic lymphoma kinase (ALK) is not expressed in Hodgkin's disease: results with ALK-11 antibody in 327 untreated patientsM Herling, G Z Rassidakis, S Viviani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 13, 2000
Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II studyA Santoro, H Bredenfeld, L Devizzi, et al.
European Journal of Haematology. Supplementum|August 7, 2001
High-dose ifosfamide and vinorelbine as salvage therapy for relapsed or refractory Hodgkin's diseaseV Bonfante, S Viviani, L Devizzi, et al.
Blood|May 16, 1998
Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin's disease at high risk of unfavorable outcomeG Nadali, L Tavecchia, E Zanolin, et al.
Pageof 7